TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world. The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. In Q4 of 2008, TMB in-licensed Tamiphosphor, a neuraminidase inhibitor for the treatment of influenza, from Academia Sinica in Taiwan and has taken that program forward. In early 2009, drug synthesis work has been conducted as well as a collaboration with NIH has been established for cross resistance testing. In addition, in collaboration with the Aaron Diamond AIDS Research Center, the development of Ibalizumab for prevention of HIV infection will be explored in a phase 1 trial in 2H 2010. This project has received grant funding from the Bill and Melinda Gates Foundation.
Headquarters
3F., No.607, Ruiguang Rd., Neihu Dist
Taipei City; Taipei City;
Contact Details: Purchase the TaiMed Biologics Inc. report to view the information.
Website: http://www.tmb.com.tw
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service